Results 161 to 170 of about 91,755 (270)

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen   +12 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu   +10 more
wiley   +1 more source

Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. [PDF]

open access: yesInt J Urol
Katayama S   +19 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam   +3 more
wiley   +1 more source

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial. [PDF]

open access: yesJHEP Rep
Neely J   +13 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

Evidence for Dose Optimization of Immune Checkpoint Inhibitors. [PDF]

open access: yesJ Immunother Precis Oncol
Limaye S, Noronha V, Prabhash K.
europepmc   +1 more source

Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer

open access: yesCancer Science, EarlyView.
This review summarizes three neoadjuvant radiotherapy techniques for stage III NSCLC, highlighting SFRT's low‐toxicity dual immune‐tumor control benefits and radioimmunotherapy's superior pathological response to guide precise multimodal treatment. ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and ...
Qinrong Mao   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy